Product Information
CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.7569 per EA under NDC 16571069401. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Jan 25, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 200; 200 mg/1; mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571069401
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; ENTACAPONE; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA213212FDA Approved
1/25/2022
TE Code
AB
On Market Since
8/5/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 21.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7569 per EA |
|---|---|
| All-time high | $0.9950 (Dec 14, 2022) |
| All-time low | $0.6636 (Aug 21, 2024) |
| 52-week high | $0.7988 |
| 52-week low | $0.7203 |
| Median price | $0.7837 |
| Average price | $0.8076 |
| Largest weekly change | +25.1% (Sep 20, 2023) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CARBIDOPA, LEVODOPA AND ENTACAPONE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CARBIDOPA, LEVODOPA AND ENTACAPONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.7569 per EA (NDC 16571069401), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB has declined 21.6%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
Since Jun 1, 2022, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB has ranged from a low of $0.6636 (Aug 21, 2024) to a high of $0.9950 (Dec 14, 2022), with a median of $0.7837 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB?
CARBIDOPA-LEVODOPA-ENTACAPONE 50-200-200 MG TAB (NDC 16571069401) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.